Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Completed · Phase 3

Conditions studied: HIV Infection, Hyperlipidemia

In brief

The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen

Key facts

Study ID

NCT00225017

Run by

Northwestern University

People needed

50

Starts

2005-06-01

Expected to finish

2008-06-01

Last updated by the study team

2012-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection
• HIV-1 RNA < 500 copies/ml
• Fasting LDL cholesterol >130 mg/dl OR fasting triglycerides >200 mg/dl
• CD4 count >100 cells/mm
• Stable antiretroviral regimen for at least 12 weeks prior to study entry that includes a protease inhibitor (PI) with or without ritonavir boosting

You may not qualify if…

• History of heart disease, uncontrolled hypertension, peripheral vascular disease
• Current non-nucleoside reverse transcriptase inhibitor (NNRTI) in the PI-containing regimen within 4 weeks
• Prior or current use of atazanavir
• Initiation of treatment with lipid-lowering drugs within 4 weeks prior to study entry

Where it is running

• University of California — San Diego, California, United States
• Northwestern Universtiy — Chicago, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• University of Wisconsin — Madison, Wisconsin, United States
• ACLIRES - Argentina S.R.L. — Buenos Aires, Argentina
• Universita degli studi di Modena e Reggio Emilia — Modena, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.